<DOC>
	<DOCNO>NCT02112045</DOCNO>
	<brief_summary>This randomized phase II trial compare well add XMO2 Filgrastim ( Granix ) melphalan stem cell transplant work treat patient multiple myeloma . Chemotherapy drug , melphalan , give prepare bone marrow stem cell transplant . Giving colony-stimulating factor , XMO2 Filgrastim ( Granix ) , may help multiple myeloma cell move patient 's bone marrow blood may sensitive treatment melphalan . It yet know whether add XMO2 Filgrastim ( Granix ) melphalan stem cell transplant work well melphalan alone treat multiple myeloma</brief_summary>
	<brief_title>A Study Granix Disrupt Bone Marrow Microenvironment Patients With Multiple Myeloma Undergoing Autologous Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Symptomatic multiple myeloma require treatment Received least two cycle regimen initial systemic therapy multiple myeloma within 212 month first dose initial therapy At least 18 year age Adequate autologous stem cell collection , define unmanipulated , cryopreserved , peripheral blood stem cell collection contain least 2 × 10^6 CD34+ cells/kg base patient body weight . Adequate organ function measure : Cardiac function : Left ventricular ejection fraction rest ≥40 % Hepatic function : Bilirubin ≤2 × ULN aspartate amino transferase/alanine amino transferase ( AST/ALT ) ≤3 × ULN Renal function : Creatinine clearance ≥40 mL/minute ( measure calculated/estimated ) Pulmonary function : Carbon monoxide diffuse capacity ( DLCO ; correct hemoglobin [ Hgb ] ) , forced expiratory volume 1 second ( FEV1 ) , force expiratory vital capacity ( FVC ) ≥50 % predict value Oxygen saturation ≥92 % room air Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Able understand willing sign IRBapproved write informed consent document Evidence multiple myeloma disease progression ( defined IMWG ) time prior ASCT Prior stem cell transplant ( autologous allogeneic ) Smoldering MM require therapy Plasma cell leukemia Systemic amyloid light chain amyloidosis Active bacterial , viral , fungal infection Seropositive human immunodeficiency virus ( HIV ) Known , active hepatitis A , B , C Infection Pregnant breastfeeding . Receiving concurrent anticancer therapy ( include chemotherapy , radiation , hormonal treatment , immunotherapy , exclude corticosteroid ) within 7 day prior ASCT plan receive treatment prior last study visit Day +100 . Hypersensitive intolerant component study drug ( ) formulation Receiving growth factor ( filgrastim , XM02filgrastim , pegfilgrastim , plerixafor , etc ) undergo apheresis &lt; 14 day prior start treatment protocol ( Day 7 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>